Lipophilic agents exhibit increased volumes of distribution with risk of accumulation in patients with obesity
The paper reports that excess adiposity induces drug-specific alterations in distribution, with lipophilic agents showing increased volumes of distribution and a consequent risk of accumulation. This finding is based on a review of recent pharmacokinetic data in perioperative patients with obesity.
This article is automatically generated from the structured evidence profile behind the claim above. Scores reflect the quality and quantity of available research, not clinical advice.
Lipophilic agents exhibit increased volumes of distribution with risk of accumulation in patients with obesity The current body of evidence comprises 1 study. EvidenceHub rates the overall confidence at 32/100 (low).
The Claim
Lipophilic agents exhibit increased volumes of distribution with risk of accumulation in patients with obesity
This conclusion is most relevant to: Perioperative patients with obesity.
What the Research Shows
The conclusion draws on 1 linked study. Highlights from the cited literature:
- ▸Perioperative drug pharmacokinetics in patients with obesity. (Current opinion in clinical nutrition and metabolic care, 2026) —
How It Works
The proposed biological pathway:
- ▸Excess adiposity alters body composition and organ function
- ▸Lipophilic drugs distribute into adipose tissue
- ▸Increased adipose mass leads to larger volume of distribution
- ▸Result: Higher risk of drug accumulation and prolonged effects
Who Might Benefit
Evidence fit by population:
- ▸Perioperative patients with obesity
Recommended Dose
N/A
Limitations & Caveats
Important context when interpreting this evidence:
- ▸The paper is a review, not a primary study, so effect sizes and specific numerical data are not provided
- ▸Pharmacokinetic evidence remains limited for several commonly used drugs (e.g., ketamine, magnesium sulfate, dexamethasone) in this population
Frequently Asked Questions
Why do lipophilic drugs accumulate more in obese patients?▼
Lipophilic drugs distribute into adipose tissue, and because obese patients have a higher proportion of body fat, the volume of distribution increases, leading to a greater risk of drug accumulation and prolonged effects.
What are examples of lipophilic agents mentioned in the paper?▼
The paper mentions remimazolam, ciprofol, and intravenous lidocaine as lipophilic agents studied in patients with obesity.
Does the paper recommend specific dosing adjustments for obese patients?▼
The paper advises an individualized approach based on pharmacokinetic principles and clinical titration, but does not provide specific dosing recommendations due to limited evidence for many drugs.
What is the main challenge in dosing drugs for obese patients?▼
The main challenge is that obesity alters drug distribution, clearance, and elimination in a drug-specific manner, making standard dosing strategies based on total body weight potentially unsafe.
References
- 1.Rousseleau D, De Baerdemaeker L. “Perioperative drug pharmacokinetics in patients with obesity..” Current opinion in clinical nutrition and metabolic care, 2026. PMID: 41995285 DOI: 10.1097/MCO.0000000000001225